Please use this identifier to cite or link to this item: http://hdl.handle.net/1893/30131
Appears in Collections:Psychology Journal Articles
Peer Review Status: Refereed
Title: Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies
Author(s): Fergusson, Dean A
Wesch, Neil L
Leung, Garvin J
MacNeil, Jenna L
Conic, Isidora
Presseau, Justin
Cobey, Kelly D
Diallo, Jean-Simon
Auer, Rebecca
Kimmelman, Jonathan
Kekre, Natasha
El-Sayes, Nader
Krishnan, Ramya
Keller, Brian A
Ilkow, Carolina
Lalu, Manoj M
Issue Date: 27-Sep-2019
Citation: Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo J, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C & Lalu MM (2019) Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. Molecular Therapy - Oncolytics, 14, pp. 179-187. https://doi.org/10.1016/j.omto.2019.05.004
Abstract: Irreproducibility of preclinical findings could be a significant barrier to the “bench-to-bedside” development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design. Using the NIH Principles and Guidelines for Reporting Preclinical Research, a core set of seven recommendations, we evaluated the completeness of reporting of preclinical OV studies. We also developed an evidence map identifying the current trends in OV research. A systematic search of MEDLINE and Embase identified all relevant articles published over an 18 month period. We screened 1,554 articles, and 236 met our a priori-defined inclusion criteria. Adenovirus (43%) was the most commonly used viral platform. Frequently investigated cancers included colorectal (14%), skin (12%), and breast (11%). Xenograft implantation (61%) in mice (96%) was the most common animal model. The use of preclinical reporting guidelines was listed in 0.4% of articles. Biological and technical replicates were completely reported in 1% of studies, statistics in 49%, randomization in 1%, blinding in 2%, sample size estimation in 0%, and inclusion/exclusion criteria in 0%. Overall, completeness of reporting in the preclinical OV therapy literature is poor. This may hinder efforts to interpret, replicate, and ultimately translate promising preclinical OV findings.
DOI Link: 10.1016/j.omto.2019.05.004
Rights: © 2019 The Author(s) This article has been published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (CC BY-NC-ND - https://creativecommons.org/licenses/by-nc-nd/4.0/).
Licence URL(s): http://creativecommons.org/licenses/by-nc-nd/4.0/

Files in This Item:
File Description SizeFormat 
1-s2.0-S2372770519300592-main.pdfFulltext - Published Version1.31 MBAdobe PDFView/Open



This item is protected by original copyright



A file in this item is licensed under a Creative Commons License Creative Commons

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.